Free Fatty Acid Effects In Type 2 Diabetes

What Was Tested

The trial (not phased) is built around Semaglutide.

Omega-3 fatty acids are natural fats found in foods such as oily fish and flaxseed.

Omega-3 fatty acids have been found to have positive effects on cardiovascular health, but there is less evidence on if they can help manage blood glucose in individuals with both cardiovascular disease and type 2 diabetes.

It had four arms (groups): Placebo (placebo comparator), Omega-3 Fatty Acid Supplementation (EPA/DHA) (experimental), Omega-3 Fatty Acid Supplementation (ALA) (experimental) and Omega-3 Fatty Acid Supplementation (EPA/DHA) and Semaglutide (experimental).

The registry classes the interventions as dietary supplement and drug.

Who Took Part

60 planned participants were the target.

It was open to people of any sex aged from 18 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

The full record lists 1 inclusion and 7 exclusion criteria; among the exclusions: those who have severe or unstable cardiovascular disease; type 2 diabetics or prediabetics who are on an anti-diabetic medication (with the exception of metformin); undergone recent major surgery or planned surgery during the study period.

How the Study Was Run

The set-up was randomized, parallel-group and single-blind.

The participants were allocated by chance, so the Semaglutide group and the comparison group should start out alike.

The Semaglutide group and the comparison group ran side by side rather than switching.

In this single-blind Semaglutide study one party knew the assignments and the other did not.

Those kept unaware of assignments: participant.

It started in 2026-09 with completion listed for 2026-12.

It ran at 1 site in United Kingdom.

Its stated primary purpose is treatment.

What Was Measured

Primary outcome: To evaluate the change in fasting glucose from baseline after 28 days of treatment, compared to each treatment group and placebo (time frame: From baseline to 28 days of treatment).

What This Means in Plain Language

Put simply, this is a not phased, randomized trial of Semaglutide in 60 people.

Its status is enrolling by invitation; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Semaglutide compound page, all human trials.